The company operates as a non-deposit taking financial institution primarily engaged in providing loans and trading in equity shares and securities.
The company lacks any identifiable competitive advantage, as evidenced by its low average ROCE of 3.9% and declining revenue growth. Its business model relies on basic lending and market trading without proprietary technology, scale, or brand power to protect margins.
Management has primarily directed capital toward related-party loans, which account for over 64% of the total loan book. Reinvestment in the core business has been minimal, and returns on equity remain stagnant at approximately 3%.
The investment collapsed as the high concentration of related-party loans, which already exceeded 64% of the book, likely devolved into a series of defaults or permanent capital leakages that management had no incentive to recover. The resignation of both statutory and internal auditors in 2024 proved to be the canary in the coal mine, signaling a breakdown in oversight that eventually led to a total loss of investor confidence. With a business model generating returns on capital below the cost of inflation and no competitive advantage to pivot, the company simply bled out through stagnant growth and administrative decay.
RichFakir rates Shreevatsaa Finance & Leasing Ltd's business quality as poor — 29/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shreevatsaa Finance & Leasing Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shreevatsaa Finance & Leasing Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shreevatsaa Finance & Leasing Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →